Indications for FLOVENT HFA:
Maintenance treatment of asthma as prophylactic therapy.
Limitations of Use:
Not for the relief of acute bronchospasm.
Previously on bronchodilators alone: initially 88mcg twice daily (approx. 12hrs apart); max 880mcg twice daily. Rinse mouth after use. Titrate to lowest effective dose after stability achieved. Re-evaluate if inadequate control.
<4yrs: not established. 4–11yrs: 88mcg twice daily (approx. 12hrs apart). Rinse mouth after use. Titrate to lowest effective dose after stability achieved. Re-evaluate if inadequate control.
FLOVENT HFA Contraindications:
Primary treatment of status asthmaticus or other acute attacks requiring intensive measures.
FLOVENT HFA Warnings/Precautions:
Maintain regular regimen. Immunosuppression. Tuberculosis. Systemic infections (eg, fungal, bacterial, viral, parasitic). Ocular herpes simplex. If exposed to chickenpox or measles, consider immune globulin or antiviral prophylactic therapies. Monitor for adrenal insufficiency when transferring from systemic steroids. Reevaluate periodically. Monitor for hypercorticism and HPA axis suppression (if occurs, discontinue gradually), growth in children, IOP, glaucoma, or cataracts. Consider eye exams if ocular symptoms develop or in long-term use. Discontinue and treat if paradoxical bronchospasm occurs; use alternative therapy. Assess bone mineral density if risk factors exist (eg, prolonged immobilization, osteoporosis, postmenopausal, tobacco use, advanced age, poor nutrition, others). Eosinophilic conditions. Hepatic impairment; monitor. Transferring from oral corticosteroids: see full labeling. Pregnancy. Nursing mothers.
FLOVENT HFA Classification:
FLOVENT HFA Interactions:
Concomitant strong CYP3A4 inhibitors (eg, ritonavir, atazanavir, clarithromycin, ketoconazole, nefazodone, others): not recommended.
Upper respiratory tract infection/inflammation, throat irritation, sinusitis, dysphonia, candidiasis, cough, bronchitis, headache; immunosuppression, adrenal suppression, bronchospasm, hypersensitivity reactions.
Generic Drug Availability:
Inhaler w. actuator (44mcg)—10.6g (120 inh); 110mcg, 220mcg—12g (120 inh)